Lifestyle intervention has been studied in 173 papers since 2014: 57 trials and 30 observational studies in people, 1 in animals, 76 reviews; 102 in the past year. The newest story, Oct 23, 2026: “Adding sleep support did not improve glucose control”.
Get new research on lifestyle intervention by email
At a glance
Human studies report improved physical function with lifestyle intervention, replicated by independent labs, and a human trial reports lower multimorbidity risk. Independent labs also report reduced depressive symptoms and body weight, while cognitive and telomere outcomes differ across human studies. Some papers declare company ties.
142 findings in 72 papers from 2014 to 2026, 19 of them since April 2026
Independent labs found the same change in people. 52 independent labs in 19 countries; 11 trials, 6 about aging.
“Randomization to lifestyle intervention was associated with 57% lower odds of progression to low ABI (adjusted OR=0.43, 95% CI 0.24-0.77, p=0.005) relative to placebo”
Humans: replicated by independent labs. Cells and mice: a single group. Worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
ADA Scientific Sessions 2026 abstract, Jun 5, 2026
What did studies of lifestyle intervention find?
94
Studies of lifestyle intervention measured 94 outcomes; the most studied are body weight (11 studies), cognitive function (5) and inflammation (3).
Body weight
↓downin humans11−9.8%
11 studies
Lifestyle intervention decreases body weight in humans (–0.79 kg vs. –0.19 kg).
“Among all participants, those in the intervention group lost more weight than those in the control group (average weight change: –0.79 kg vs. –0.19 kg, P = 0.001) and had a greater reduction in waist circumference (–1.70 cm vs. –0.85 cm, P = 0.002) during the first visit.”
Lifestyle intervention decreases body weight in humans (prediabetes with overweight/obesity, maintainers vs non-responders) (mean difference -4.0 kg; 95% CI -5.8, -2.2 kg).
“compared with non-responders, maintainers achieved greater weight loss (mean difference -4.0 kg; 95% CI -5.8, -2.2 kg)”
Human trialprediabetes with overweight/obesity, maintainers vs non-responders3 years
Lifestyle intervention decreases body weight in rejoiners compared to previous intervention (weight: -1.5% vs. -3.5%, VAT: -7.2% vs. -33.3%, deep SAT: -4.0% vs. -31.9%, superficial SAT: -3.3% vs. -25.4% (all FDR < 0.05)).
“In response to T2, rejoiners exhibited attenuated improvements compared to those achieved during their previous T1 intervention (weight: -1.5% vs. -3.5%; VAT: -7.2% vs. -33.3%”
Human trialin rejoiners compared to previous interventiontrial 2
Lifestyle intervention decreases body weight in humans (whole group) (-6.6 ± 2.9 kg).
“Patients lost 6.6 ± 2.9 kg, with a BMI change of −2.62 ± 1.1 Kg/m2, a waist circumference reduction of 6.5 ± 6.9 cm, an average fat mass reduction of 1.27 ± 1.68%, and fat-free mass increase of 1.3 ± 1.63%.”
Lifestyle intervention decreases body weight in lower than median baseline TL group compared to higher baseline TL group (−8.1 ± 2.7 vs. −6.1 ± 4.6 Kg, p = 0.03).
“greater weight loss (−8.1 ± 2.7 vs. −6.1 ± 4.6 Kg, respectively, p = 0.03)”
Human trialin lower than median baseline TL group compared to higher baseline TL group1-year
Lifestyle intervention increases insulin sensitivity in humans (obesity and type 2 diabetes; Study I) (Clamp-derived insulin sensitivity +50%; HOMA-IR -26%).
“Clamp-derived insulin sensitivity increased by 50% (Study I), and HOMA-IR decreased by 26% in both studies.”
Human trialobesity and type 2 diabetes; Study I1 year
Lifestyle intervention improves insulin sensitivity in silico (impaired glucose tolerance) (Insulin-dependent glucose clearance declined 2.1%/year with intervention versus 8.1%/year due to disease progression).
“translated to a much slower deterioration of the first-phase insulin secretion and insulin sensitivity.”
Lifestyle intervention decreases depressive symptoms in humans.
“The results demonstrated significant indirect effects from intervention receipt to decreased depressive symptoms via increased activity frequency and activity significance.”
Lifestyle intervention increases telomere length in lower than median baseline TL group compared to higher baseline TL group (+0.57 ± 1.23 vs. −2.15 ± 1.13 kbp, p = 0.04).
“At T12, the L-TL group when compared to H-TL showed TL elongation (respectively, +0.57 ± 1.23 vs. −2.15 ± 1.13 kbp, p = 0.04)”
Human trialin lower than median baseline TL group compared to higher baseline TL group1-year
Lifestyle intervention showed no clear effect on daily step count in the IFG group (mean 71 steps/day (95% CI −429, 571)).
“The intervention increased the mean number of steps/day relative to usual care by 247 (95% CI 4, 491) in the normoglycaemia group, 523 (95% CI 229, 818) in the IGT group, and 808 (95% CI 402, 1213) in the IFG+IGT group, but not in the IFG group (mean 71; 95% CI −429, 571).”
Lifestyle intervention increases daily step count in normoglycaemia, IGT, and IFG+IGT groups (+523 steps/day (95% CI 229, 818) in IGT).
“The intervention increased the mean number of steps/day relative to usual care by 247 (95% CI 4, 491) in the normoglycaemia group, 523 (95% CI 229, 818) in the IGT group, and 808 (95% CI 402, 1213) in the IFG+IGT group, but not in the IFG group (mean 71; 95% CI −429, 571).”
Human trialin normoglycaemia, IGT, and IFG+IGT groupsup to 48 months
Lifestyle intervention showed no clear effect on daily step count in individuals with impaired fasting glucose (IFG) (mean 71 steps/day (95% CI -429, 571)).
“but not in the IFG group (mean 71; 95% CI -429, 571).”
Human trialin individuals with impaired fasting glucose (IFG)up to 48 months
Lifestyle intervention increases daily step count in individuals with impaired glucose tolerance (IGT) (523 steps/day (95% CI 229, 818)).
“The intervention increased the mean number of steps/day relative to usual care by 247 (95% CI 4, 491) in the normoglycaemia group, 523 (95% CI 229, 818) in the IGT group”
Human trialin individuals with impaired glucose tolerance (IGT)up to 48 months
Lifestyle intervention improves physical health in humans (as-treated analysis with inverse probability of censoring weights) (B = 2.28, 95% CI [2.48, 2.75]).
“AST analysis showed improvements in both the mental (B = 0.77, 95% CI [0.49, 1.04]) and physical (B = 2.28, 95% CI [2.48, 2.75]) composites.”
Human trialas-treated analysis with inverse probability of censoring weightsn = 424
Lifestyle intervention decreases oxidative stress and ROS signaling in humans.
“It can also be observed that at T1, the percentage changes in plasma values of markers of oxidation, such as TBARS, IsoP and 8OHdG compared to T0, were significantly greater in control group versus LSP group ( C).”
Lifestyle intervention decreases oxidative stress and ROS signaling in human cells (HUVEC treated with plasma from LSP group vs T0).
“Finally, at T1, in HUVEC treated with plasma from LSP group only we found an increase of the mitochondrial membrane potential and a reduction of ROS and MitoROS release”
CellsHUVEC treated with plasma from LSP group vs T0
Lifestyle intervention decreases 8-hydroxy-2'-deoxyguanosine in humans (-62 % vs -20 %).
“Instead, the levels of 8OHdG were reduced both in LSP group and control group, at T1, although at a lesser extent in control group (−20 % in control group: from 46 ng/ml of T0 to 36 ng/ml of T1;-62 % in LSP group: from 49 ng/ml of T0 to 18 ng/ml of T1; p < 0.05; E, F”
Lifestyle intervention decreases body mass index in young adulthood overweight (YAO) trajectory (β = -0.52, p = 0.018).
“Our results showed that YAO and ECO trajectories in the intervention group were concomitant with lower BMI levels than in the control group, with the highest estimated effect in the latter (β=-0.52 and p = 0.018; β= -1.48 and p < 0.001, respectively).”
Human trialin young adulthood overweight (YAO) trajectorymedian follow-up of 16.1 yearsn = 780
Lifestyle intervention decreases body mass index in humans (young adulthood overweight trajectory) (β=-0.52, p=0.018).
“Only Young adulthood overweight and Early childhood increasing obesity were affected by the intervention and were concomitant with lower BMI levels than the control group”
Human trialyoung adulthood overweight trajectorymedian 16.1 years
Lifestyle intervention lowers the risk of type 2 diabetes in humans.
“Lifestyle intervention (dietary energy reduction and lower glycemic load plus structured exercise) is first-line and cost-effective; DPP/DPPOS show substantial diabetes risk reduction.”
Lifestyle intervention lowers the risk of cardiovascular disease in humans.
“Modifications in lifestyle, such as quitting smoking, regular physical activity, following a heart-healthy diet plan, and getting adequate sleep, can significantly reduce the risk of CVD.”
Lifestyle intervention is associated with net weight loss after semaglutide discontinuation in humans (12 months after semaglutide discontinuation) (-5.8 ± 0.5% vs -3.3 ± 0.3%).
“At 12 months following discontinuation, net weight loss remained greater among LI participants (-5.8 ± 0.5%) compared to nonparticipants (-3.3 ± 0.3%, p<0.01)”
Humans12 months after semaglutide discontinuation12 months following discontinuationn = 2,403
Lifestyle intervention is associated with telomere length in humans (P = 0.02 vs controls; P = 0.003 vs medically treated; F(2,54) = 4.98, P = 0.01 overall).
“Telomeres were shorter in the GDM lifestyle intervention group compared to both controls (P = 0.02) and medically treated pregnancies (P = 0.003).”
Humansmale placenta only; compared with controls and with metformin and/or insulin treated pregnanciesplacentamales
Human trials report improved Personal-MetaboHealth in at-risk participants and increased steps with impaired glucose tolerance, but not impaired fasting glucose. One human study reports increased weight loss in men at the contemplation stage, but no overall effect after insufficient initial weight loss.
An eight-week randomized trial in 196 adults with prediabetes and short sleep found no significant added glucose or weight-loss benefit over lifestyle support alone.An eight-week randomized trial in 196 adults with prediabetes and short sleep found no significant added glucose or weight-loss benefit over lifestyle support alone.